MBP-134 is under clinical development by Mapp Biopharmaceutical and currently in Phase I for Ebolavirus Infections (Ebola Hemorrhagic Fever). According to GlobalData, Phase I drugs for Ebolavirus Infections (Ebola Hemorrhagic Fever) have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MBP-134’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MBP-134 is under development for the treatment of Sudan Ebolavirus infection. The drug candidate is a pan-Ebolavirus immunotherapeutic cocktail of two monoclonal antibodies. It is administered through intravenous route.
Mapp Biopharmaceutical overview
Mapp Biopharmaceutical is a healthcare service provider that offers drug development services. The company’s pipeline products include MB66 intended to block sexual transmission of genital herpes and HIV as a rapidly dissolving film that releases anti-viral monoclonal antibodies to the vaginal mucosa and MB66 is a multipurpose prevention technology intended to block sexual transmission of genital herpes and HIV. It also provides ZMapp is composed of three humanized monoclonal antibodies manufactured in Nicotiana. Mapp Biopharmaceutical offers services such as Biacore X100 analysis services, accurate affinity determination, and mapping of protein-protein interaction domains, among others. The company provides its products and services to healthcare, medical and pharmaceutical sectors. Mapp Biopharmaceutical is headquartered in San Diego, California, the US.
For a complete picture of MBP-134’s drug-specific PTSR and LoA scores, buy the report here.